Metastatic melanoma: anti-ipilimumab antibodies tied to worse OS

Access to the full content of this site is available only to registered healthcare professionals. Register to read more


  • In patients with metastatic melanoma treated with ipilimumab, low serum levels of ipilimumab and development of antidrug antibodies (ADAs) are associated with reduced survival.

Why this matters

  • Little is currently known about the clinical effects of ADA development.